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Abstract
Objectives: The transcription factor SOX2 (3q26.3-q27) is an embryonic stem cell factor contributing to the induction of
pluripotency in terminally differentiated somatic cells. Recently, amplification of the SOX2 gene locus has been described in
squamous cell carcinoma (SCC) of different organ sites. Aim of this study was to investigate amplification and expression
status of SOX2 in sinonasal carcinomas and to correlate the results with clinico-pathological data.
Materials and Methods: A total of 119 primary tumor samples from the sinonasal region were assessed by fluorescence in-
situ hybridization and immunohistochemistry for SOX2 gene amplification and protein expression, respectively. Of these, 59
were SSCs, 18 sinonasal undifferentiated carcinomas (SNUC), 10 carcinomas associated with an inverted papilloma (INVC), 19
adenocarcinomas (AD) and 13 adenoid cystic carcinomas (ACC).
Results: SOX2 amplifications were found in subsets of SCCs (37.5%), SNUCs (35.3%), INVCs (37.5%) and ADs (8.3%) but not in
ACCs. SOX2 amplification resulted in increased protein expression. Patients with SOX2-amplified sinonasal carcinomas
showed a significantly higher rate of tumor recurrences than SOX2 non-amplified tumors.
Conclusion: This is the first study assessing SOX2 amplification and expression in a large cohort of sinonasal carcinomas. As
opposed to AD and ACC, SOX2 amplifications were detected in more than 1/3 of all SCCs, SNUCs and INVCs. We therefore
suggest that SNUCs are molecularly closely related to SCCs and INVCs and that these entities represent a subgroup of
sinonasal carcinomas relying on SOX2 acquisition during oncogenesis. SOX2 amplification appears to identify sinonasal
carcinomas that are more likely to relapse after primary therapy, suggesting that these patients might benefit from a more
aggressive therapy regime.
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Introduction
Recent advances in genetic profiling have led to more refined
molecular classifications of specific tumor entities, providing novel
diagnostic, prognostic and predictive biomarkers and paving the
way for rational therapy regimens. However, the genetic landscape
of rare tumor entities remains largely unelucidated. Malignant
tumors of the paranasal sinuses or the nasal cavity account for less
than 1% of all cancers and for about 3% of all malignant
otorhinolaryngeal tumors [1]. The annual incidence rate is 0.5 to
1.0 per 100 000 people [2]. These tumors mainly occur within the
maxillary sinus (,60%) or the nasal cavity (,30%) [1]. The most
frequent histological entity is squamous cell carcinoma (SCC). The
majority of patients presents at an advanced stage of disease due to
a lack of early disease symptoms [3]. If at all feasible, complete
resection of these mostly locally advanced tumors often results in
severe cosmetic and functional compromise. Despite improve-
ments in the field of surgery and radiochemotherapy, most
patients suffering from carcinomas of the sinonasal origin have an
unfavourable prognosis even in the setting of aggressive therapy
[3], [4]. While controversy persists in determining the optimal
therapeutic approach in a given patient, prognostic markers
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identifying patients who will benefit from more aggressive
treatment and novel molecular targeted therapies are urgently
needed.
The SOX2 (SRY (sex determining region Y)-box 2) gene is
located at the chromosomal locus 3q26.33 and encodes for a
transcription factor containing the high mobility group (HMG)
DNA-binding domain. SOX2 is essential for maintenance of the
pluripotency of embryonic stem cells and self-renewal of tissue-
specific adult stem cells [5], [6], [7]. When co-expressed with other
embryonic stem cell factors like NANOG and Oct3/4, SOX2 is able
to re-induce pluripotency in terminally differentiated cells [8], [9],
[10]. More recently, deregulated SOX2 expression was noted in a
variety of tumors [11], [12] suggesting that SOX2 also plays
important roles as an oncogene. SOX2 amplification was first
detected in lung SCCs with reported frequencies varying from
20% to 60% [13], [14], [15], [16], [17]. At much lower
frequencies (6%) SOX2 amplification has also been identified in
adenocarcinoma of the lung [15], [16], [17], [18]. Apart from
lung, aberration of this chromosomal region has been described in
SCC of the esophagus [13], skin, cervix, and penis [12]. In the
head and neck region, Freier et al. found recurrent SOX2
amplification in 52% of oral SCCs [19].
To our knowledge, currently there is no data describing the role
of SOX2 in carcinomas of the sinonasal region. We assembled a
clinically well-characterized cohort comprising the most common
sinonasal carcinomas, namely SCC, sinonasal undifferentiated
carcinoma (SNUC), carcinoma associated with an inverted
papilloma (INVC), adenocarcinoma (AD) and adenoid cystic
carcinoma (ACC) and assessed for SOX2 amplification and
protein expression status. Furthermore, we evaluated the prog-
nostic impact of SOX2 amplification and SOX2 protein expression
levels by correlating these results with clinico-pathological data.
Materials and Methods
Cohort Characterization and Clinico-pathological Data
Collection
A total of 119 patients with sinonasal carcinomas deriving from
independent cohorts (University of Bonn (n= 87), University of
Cologne (n= 27), Ludwig Maximilian University of Munich (n= 3)
and University of Erlangen (n= 2)) were included in our study.
In detail, the Bonn cohort consisted of 38 sinonasal SCCs with 7
corresponding regional lymph node metastases, 13 SNUCs with 1
corresponding lymph node metastasis, 10 INVCs with 2 corre-
sponding lymph node metastases, 13 ADs, and 13 ACCs, as well as
35 samples of normal sinonasal respiratory tissue. 21 sinonasal
SCCs, and 6 ADs were retrieved from the University of Cologne. 3
and 2 SNUCs were retrieved from the University of Munich and
Erlangen, respectively. By employing NUT-antibody (NUT
C52B1, Cell Signaling Technology, Beverly, MA, USA) via
immunohistochemistry, two NUT-midline carcinomas (NMC)
previously misdiagnosed as SNUCs have been excluded from
our cohort.
All patients were treated at the head and neck departments of
the listed University Hospitals. Clinico-pathological data, includ-
ing follow-up, were obtained via review of the patients’ medical
charts, which were available only for the Bonn cohort. The mean
duration of follow-up was 33637 months.
The study was approved by the internal review board of the
University Hospital of Bonn (#267/11). Due to the fact that we
used anonymized patients’ FFPE material in a retrospective
manner and the patients are no longer being treated at the clinic
our internal review board disclaimed a written or verbal patients’
consent to participate in this study.
Tissue Microarray (TMA) Construction
Formalin-fixed, paraffin-embedded samples were cut into 4-
mm thick sections, mounted on slides, and stained with
hematoxylin and eosin. Histology was confirmed by two
pathologists (S.P. and F.G.) to reassure diagnosis and to mark
carcinoma tissue as target areas for TMA construction. TMA
recipient blocks were constructed using a semiautomatic tissue
microarray instrument (Beecher Instruments, Sun Prairie, WI).
Three representative 0.6 mm cores of viable tissue from each
tumor, its corresponding lymph node metastasis and benign
tissue were included.
Fluorescence In-situ Hybridization Assay (FISH)
SOX2 amplification status was assessed on TMAs. For this
purpose we performed FISH assays as described previously [13].
In brief, the SOX2 target probe (red fluorescent signal) probe
spanning the locus 3q26.33 (BAC clone CTD-2348H10,
Invitrogen, Carlsbad, CA, USA) and a commercially available
centromeric probe on chromosome 3 (Metasystems, Altlussheim,
Germany) were selected for hybridisation. Only nuclei display-
ing green reference signals were included for the determination
of the SOX2 copy number status. All TMA slides were analyzed
by two independent evaluators (A.S. and F.G.) under a 63x oil
immersion objective with a fluorescence microscope (Zeiss, Jena,
Germany). In each case, we assessed at least 100 tumor cell
nuclei. A wild-type (WT) nucleus displayed the same amount of
red and green signals in a cell. A sample was considered
amplified if at least 30% nuclei displayed the SOX2 amplifica-
tion. Amplification status was defined according to the criteria
of Wilbertz et al. [17]. In detail, a low level amplification (LLA)
was defined as additional 2–9 red target signals exceeding the
number of green signals. Additional ten or more red target
signals or clusters of red target gene signals as compared to the
green reference signals were defined as high-level amplification
(HLA).
Immunohistochemistry (IHC)
Immunohistochemistry was performed with the Ventana
Discovery automated immunostaining system (Ventana Medical
Systems, Tucson, AZ, USA), using Ventana reagents. Paraffin
sections (5 mm) were mounted on superfrost slides, deparaffinised
in anorganic buffer and then pretreated with EDTA-based buffer
(pH 8.4). In order to assess protein expression status the primary
antibody (polyclonal goat anti–human SOX2 antibody, AF2018;
R&D Systems, Minneapolis, MN; dilution, 1:40, heat-induced
epitope retrieval) was applied. Dilution was achieved with a
Ventana diluent. The bound antibody was visualized using a
biotinylated detection kit (diaminobenzidine and horseradish
peroxidase (DABMap-kit, Ventana)). Counterstaining was per-
formed with hematoxylin and Blueing Reagent (Ventana).
Sections were washed, dehydrated in an ascending alcohol series
and covered using Cytoseal. TMAs were digitalized using the Zeiss
MIRAX DESK scanner. We then used a semi-automated
quantitative image analysis software (Definiens Architect XD
1.2, Definiens, Munich, Germany) in order to obtain a continuous
spectrum of average nuclear brown staining intensity in arbitrary
units (maximum range of readout 0–200) for the tumor areas of
each core.
Statistics
For ordinally scaled nonparametric data, the Wilcoxon-Mann-
Whitney-U Test was used. In case of more than two groups, we
used the extended Wilcoxon-Mann-Whitney-U Test. Fisher’s
SOX2 Amplification in Sinonasal Cancer
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exact test was used for computing statistical significance.
Comparison of mean values was done by t-test or analysis of
variance in case of more than two groups. Two groups according
to the median value were defined for age (66 years). P values of
p#0.05 were considered to be statistically significant. All statistical
analysis and graphical output were done with R version 2.13.0 on
MAC OS X 10.6.8 system.
Results
SOX2 Amplification Status (FISH)
Of the 119 tumor samples 97 were assessable and 22 samples
were not assessable due to technical reasons. Of assessable SCCs
(48/59), we found wild-type SOX2 in 62.5% (30/48), LLA in
35.4% (17/48) and HLA in 2.1% (1/48). Examples of each SOX2
copy number status are illustrated in Figure 1. Of all assessable
SNUCs (17/18), 64.7% (11/17) displayed wild-type SOX2, 29.4%
(5/17) LLA and 5.9% (1/17) HLA. Of assessable ADs (13/19)
wild-type SOX2 was found in 92.3% (12/13) and LLA in 7.7%
(1/13). INVCs (8/10 assessable) displayed wild-type SOX2 in
62.5% (5/8) and LLA in 37.5% (3/8). All assessable ACCs (11/13)
uniformly showed wild-type SOX2. None of the 35 samples of
normal respiratory tissue revealed evidence of SOX2 amplification.
Results are summarized in Table 1.
SOX2 Protein Expression Levels (IHC)
SOX2 protein expression was highly heterogenous among the
analyzed cohort samples, resulting in values from 0 to 189
(arbitrary units). Comparing the different histologies, SCC
exhibited the highest protein expression (102640) followed by
INVC (86627), SNUC (82646), AD (45630) and ACC
(38630). Mean SOX2 expression in SCC, INVC and SNUC
was significantly higher in SOX2 amplified cancer samples
(125640) than in non-amplified tumors (80633) (p,0.001)
(Figure 1 and 2). Interestingly, 14% of assessable non-amplified
samples also displayed a high SOX2 protein expression (more
than the median protein expression of amplified tumors)
indicating that SOX2 activation can occur through alternative
mechanisms.
Figure 1. SOX2 FISH and SOX2 IHC. Above: representative FISH images of sinonasal squamous cell carcinoma samples without SOX2
amplification (A), SOX2 low level amplification (B) and SOX2 high level amplification (C). Below: representative immunohistochemical stains of weak
nuclear SOX2 expression in case of wildtype SOX2 (D) and strong nuclear SOX2 expression in case harbouring SOX2 amplification (E).
doi:10.1371/journal.pone.0059201.g001




Cases LLA HLA WT
SCC 59 48 17 (35.4%) 1 (2.1%) 30 (62.5%)
SNUC 18 17 5 (29.4%) 1 (5.9%) 11 (64.7%)
AD 19 13 1 (7.7%) 0 12 (92.3%)
INVC 10 8 3 (37.5%) 0 5 (62.5%)
ADC 13 11 0 0 11 (100%)
Total 119 97 26 (26.8%) 2 (2.1%) 69 (71.1%)
LLA: SOX2 low level amplification; HLA: SOX2 high level amplification; WT: SOX2
wildtype; SCC: squamous cell carcinoma; SNUC: sinonasal undifferentiated
carcinoma; AD: adenocarcinoma; INVC: carcinoma out of an inverted sinonasal
papilloma; ACC: adenoid cystic carcinoma.
doi:10.1371/journal.pone.0059201.t001
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SOX2 Amplification and Expression in Metastatic Lymph
Nodes in Sinonasal SCC, INVC and SNUC
Furthermore, we analysed SOX2 amplification and expression in
primary sinonasal SCCs, INVs and SNUCs and their correspond-
ing metastatic lymph nodes of the Bonn cohort (n = 61).
Information on the lymph node status was available in 54 out of
61 patients. Of these, 10 displayed regional lymph node
metastases. 7/10 samples of lymph node metastases were
assessable. 5 out of these 7 (71%) patients did not display SOX2
amplification either in the primary tumor or in the metastasis
(Figure 3). One patient harboured a SOX2 LLA in the primary
tumor but not in the lymph node metastasis. One patient with
SOX2 LLA in the primary tumor also exhibited a LLA in the
corresponding lymph node metastasis. No differences in SOX2
protein expression were noted across these samples (Figure 3).
Prognostic Value of SOX2 Amplification/Expression
In order to assess the prognostic value of SOX2 amplification on
the clinical course of disease in sinonasal SCCs, INVCs and
SNUCs, we correlated the SOX2 amplification status with the
incidence of tumor recurrence. Irrespective of the specific
histology, patients with SOX2-amplified SCCs, SNUCs, and
INVCs experienced a significantly higher incidence of recurrence
(15/20; 75%) as opposed to non-amplified carcinomas (13/31;
42%) (p = 0.02) (Figure 4). However, we could not detect a
significant correlation between SOX2 protein expression levels
and tumor recurrence. In tendency, the overall survival rate after 3
years was lower for SOX2-amplified patients as compared to SOX2
non-amplified patients (25.7% versus 58.6%). However, this did
not reach statistical significance (p = 0.28).
Correlation of SOX2 Amplification/Expression Status with
Clinico-pathological Data
Within the group of patients suffering from SCC, INVC and
SNUC, age and gender were similar in patients with SOX2 wild-
type or amplified tumors. No association between SOX2 amplifi-
cation status and patient’s smoking status, tumor differentiation or
stage was noted (Table 2). SOX2 protein expression status did not
correlate with age, gender, smoking status, tumor differentiation or
stage.
Discussion
Deletion of tumor suppressor genes and/or amplification of
oncogenes are frequently found in malignant tumors and play a
critical role in tumorigenesis [20], [21]. Identification and
characterization of these genetic pathways is necessary to
understand tumor initiation, development and biology leading to
the discovery of useful diagnostic, prognostic and predictive
markers as well as potential targets for actionable therapies [21],
[22]. The transcription factor SOX2, which is located at 3q26.33
controls cell self-renewal and differentiation processes in plurip-
otent stem cells and also during early embryonic development.
Moreover, it has been identified as the driving oncogene of the 3q
amplicon in SCCs of different organ sites, implying that SOX2 is
involved in SCC carcinogenesis [17] of different organ sites. In this
study, we identified SOX2 amplification as a novel event in
carcinomas of the sinonasal region. 119 samples of sinonasal
carcinomas were assessed in a semi-quantitative manner. Whereas
SOX2 amplification occurred in about 35% of SCCs, SNUCs and
INVCs, it was a rare event in ADs and not detected in ACCs. To
Figure 2. SOX2 protein expression levels. SOX2-amplified sinonasal tumors exhibited significantly higher SOX protein expression than non-
amplified tumors.
doi:10.1371/journal.pone.0059201.g002
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date, a definite histological identification and subcategorization of
SNUCs as an independant tumor entity remains challenging.
Interestingly, molecularbiological features such as SOX2 ampli-
fication and expression display striking similarities between
undifferentiated SCCs and SNUCs. This may prove a close
relationship between these two tumor entities, or even suggest that
in fact SNUCs are dedifferentiated SCCs.
Since SOX2 protein expression levels were higher in SCCs,
SNUCs and INVCs compared to ADs and ACCs regardless
SOX2 gene copy number status, we hypothesize that SOX2 plays
a more important role in these 3 tumor entities. Reflecting a gene-
dosage effect, SOX2 amplified carcinomas displayed a significantly
higher SOX2 protein level than non-amplified carcinomas.
However, we detected a high SOX2 protein expression in 14%
of non-amplified carcinomas suggesting that in these cases the
aberrant protein expression is driven by mechanisms other than
gene amplification, as also previously reported by us in breast and
ovarian cancers [11]. However, similar to SCC of the lung [17],
our results imply that in sinonasal SCCs, INVCs and SNUCs
increased SOX2 gene copy numbers are the main driver of
increasing SOX2 protein levels. There was a high correlation
between SOX2 protein expression in primary tumors and lymph
nodes metastases with all SOX2 expressing primary tumors also
having SOX2 positive lymph node metastases. Mean SOX2
expression levels were comparable in metastatic versus primary
tumor tissues. These data suggest that SOX2 expression is an early
Figure 3. SOX2 amplification status and protein expression in primary tumors and their corresponding lymph node metastases.
Above, SOX2 amplification status of primary sinonasal tumors and corresponding lymph node metastases. In most cases, SOX2 gene copy number
status is transferred into corresponding lymph node metastases. Below, we demonstrate SOX2 protein expression levels of lymph node metastases,
their corresponding metastasized primary tumors (PT) and non metastasized primary tumors (PT). SOX2 protein expression level is not an
independent predictor for the occurrence of lymph node metastases.
doi:10.1371/journal.pone.0059201.g003
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event during tumorigenesis rather than a genetic event acquired
during tumor progression, similar to our observations in breast
cancer where aberrant SOX2 expression was already observed in
the earliest stages of tumor development [11]. One of the analyzed
samples showed loss of SOX2 amplification in metastatic versus
primary tumor tissue. This could be explained by clonal
heterogeneity in this individual tumor with additional genetic
events strongly driving metastasis in a SOX2-negative population.
However, because of the very limited number of paired samples of
primary tumor and corresponding metastatic lymph node, future
studies on larger cohorts are needed to draw solid conclusions.
More recently, SOX2 and other embryonic proteins have been
hypothesized to identify the tumor stem cell subpopulation within
malignancies [14], [23], [24]. Tumor stem cells are thought to
exhibit enhanced resistance to conventional anti-tumor therapies
causing tumor recurrences and metastases [25]. In our study,
SOX2 was homogenously expressed within the tumors. This
indicates that SOX2 does not serve as a tumor stem cell marker in
sinonasal carcinoma, but rather functions as a ubiquitously
activated oncogene.
Concerning the prognostic value of SOX2 expression in tumors,
contradictory results have been reported in different tumor
entities, depending on their localization and histology: while some
studies suggest that increased SOX2 expression is associated with a
prolonged overall survival in patients suffering from lung SCCs
[13], [17], [26] others refer to a high SOX2 expression as a
marker of poor prognosis in esophageal SCC [27], oral SCC [28]
or lung AD [18]. Although limited by a rather low number of
cases, patients harbouring SOX2 amplifications exhibited a
significantly higher rate of tumor recurrences than patients lacking
this event. This has two major implications. Firstly, SOX2 could
serve as a valuable marker identifying patients with higher risk of
disease recurrence. These patients could consecutively be intro-
duced to closer follow-up strategies. Secondly, patients harbouring
Figure 4. Tumor recurrence in relation to the SOX2 amplification status. Incidence of tumor recurrence (red bars) versus relapse-free survival
(white bars) of SOX2-amplified (A) and non-amplified (2) tumors subdivided into the different tumor histologies. Due to the low number of patients,
p-value was calculated for all tumor entities together (SCC: squamous cell carcinoma; INVC: carcinoma out of an inverted sinonasal papilloma SNUC:
sinonasal undifferentiated carcinoma).
doi:10.1371/journal.pone.0059201.g004
Table 2. Association of clinico-pathological data with SOX2
amplification status.
SOX2 Amplification SOX2 Wild-Type p-value
Gender 0.50
male 13 (35.1%) 24 (64.9%)
female 8 (44.4%) 10 (55.6%)
Age, median 0.58
,66 13 (40.6%) 19 (59.4%)
$ 66 7 (31.8%) 15 (68.2%)
smoking habits 0.72
smoker 8 (42.1%) 11 (57.9%)
non-smoker 5 (31.2%) 11 (68.6%)
Overall survival 0.28
1 year survival 65% 70%
2 year survival 60% 63%
3 year survival 26% 59%
Tumor stage 0.39
T1 2 (22.2%) 7 (77.8%)
T2 6 (50%) 6 (50%)
T3 2 (22.2%) 7 (77.8%)
T4 11 (44%) 14 (56%)
Tumor differentiation 0.17
well 1 (16.6%) 5 (83.4%)
moderate 9 (32.1%) 19 (67.9%)
poor 4 (66.6%) 2 (33.4%)
doi:10.1371/journal.pone.0059201.t002
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SOX2 amplification could profit from more aggressive primary
therapy strategies, also reducing their risk of relapse.
We did not find a statistically significant association between
SOX2 amplification/expression status and the overall survival rate
or prognostic factors such as tumor stage and regional lymph node
status. Further studies performed on larger cohorts are needed to
explore the value of SOX2 as a prognostic marker in sinonasal
carcinoma.
In summary, we identified SOX2 as a novel oncogene expressed
in a distinct subgroup of sinonasal SCCs, INVCs and SNUCs.
SOX2 could serve as a valuable prognostic marker in these rare
tumor entities.
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